When was Roivant Sciences founded?

Roivant Sciences was founded in 2014.

Where is Roivant Sciences located?

Roivant Sciences is headquartered in New York City, United States.

Who is the current CEO of Roivant Sciences?

Matthew Gline of Roivant Sciences.

How many employees does Roivant Sciences have?

As of Dec 31, 2024, the latest employee count at Roivant Sciences is 750.

Is Roivant Sciences a funded company?

Roivant Sciences is a funded company, having raised a total of $1.3B across 5 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round.

When was the latest funding round of Roivant Sciences?

Roivant Sciences' latest funding was a $***** PE round on Nov 13, 2018, with participation from 2 investors. Its primary sector is Diversified Pharmaceuticals. In United States, the Diversified Pharmaceuticals sector has seen $284M in funding in 2026 to date.

What is the annual revenue of Roivant Sciences?

Annual revenue of Roivant Sciences is between $10M and $50M as on Mar 31, 2025

Where does Roivant Sciences rank among its competitors?

Roivant Sciences ranks 7th amongst 1736 active competitors, of which 85 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was AstraZeneca, which secured $6.05M in Jul, 2025.

Who are the top competitors of Roivant Sciences?

Roivant Sciences' top competitors include AbbVie, Amgen and Gilead. Among them, AstraZeneca secured the most recent funding round in July, 2025.

Roivant Sciences - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Roivant Sciences is developing therapeutics in disease areas such as neurology, oncology, rare diseases, and endocrinology. Its CNS drug pipeline include Intepirdine, a selective 5-HT6 receptor antagonist for mild-to-moderate Alzheimer's disease (phase 3), dementia with Lewy bodies (DLB) (phase 3), gait and balance impairments in dementia (phase 2); Nelotanserin, agonist of the 5-HT2A receptor for visual hallucinations in Lewy body dementia (phase 2), REM behavior disorder (RBD) in DLB (phase 2/3); RVT-103 and RVT-104 for Alzheimer's disease (phase 1) and Lewy body dementia (phase 1). Other drugs in the pipeline include Relugolix for uterine fibroids (phase 3), endometriosis (phase 3) and prostate cancer (phase 3). It is also developing drugs for atopic dermatitis (phase 2), autism (phase 2), female infertility (phase 2) and Farber disease (phase 2).

Website: www.roivant.com/
Social
Email ID: *****@roivant.com

Key Metrics

Founded Year

2014

Location

New York City, United States

Stage

Public

Total Funding

$1.3B in 5 rounds

Latest Funding Round

PE, Nov 13, 2018, $*****

Investors

NovaQuest Capital Management & 9 more

Ranked

7^th among 1736 active competitors

Annual Revenue

$10M - $50M as on Mar 31, 2025

Employee Count

750 as on Dec 31, 2024

Investment & Acquisitions

Proxima & 11 more

Similar Companies

AbbVie & 1763 more

Exit Details

Public

View Roivant Sciences' full profile

Roivant Sciences is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ROIVANT SCIENCES HOLDINGS LIMITED CIN: 10317613 , United Kingdom, Active	Aug 07, 2016	-	251 (As on Mar 31, 2019)
ROIVANT SCIENCES LTD. CIN: 1635088 , United States, Active	Feb 23, 2014	$10M - $50M (As on Mar 31, 2025)	-	-
ROIVANT SCIENCES, INC. CIN: 465630757 , United States, Active	May 06, 2014	-	783 (As on Dec 31, 2024)	-

Roivant Sciences got listed on Oct 01, 2021.

Click here to take a look at Roivant Sciences's IPO in detail

Roivant Sciences has raised a total funding of $1.3B over 5 rounds. Its latest funding round was a PE round on Nov 13, 2018 for $*****. 2 investors participated in its latest round. Roivant Sciences has 10 institutional investors.

Here is the list of recent funding rounds of Roivant Sciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 13, 2018	1636587	PE	9469268	6240035	1758623	6318538
Apr 01, 2018	4561102	Grant (prize money)	1410310	2447884	1378282	HHS
Aug 09, 2017	2664313	PE	5093272	8018983	SoftBank Vision Fund	Dexcel

Access funding benchmarks and valuations. Sign up today!

View details of Roivant Sciences's funding rounds and investors

The founders of Roivant Sciences is Vivek Ramaswamy. Matthew Gline is the CEO of Roivant Sciences.

Here are the details of Roivant Sciences' key team members:

Vivek Ramaswamy: Founder of Roivant Sciences and founder of 2 other companies, Axovant Sciences and Metavant Sciences. They are also an angel investor in 4 startups.
Contact Info: 1 email address
Matthew Gline: CEO of Roivant Sciences.
Contact Info: 1 email address

View details of Roivant Sciences's Founder profiles and Board Members

Roivant Sciences' employee count trend

Roivant Sciences has 750 employees as of Dec 24. Here is Roivant Sciences's employee count trend over the years:

Employee count trend for Roivant Sciences

Uncover Roivant Sciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Roivant Sciences include AbbVie, Amgen and Gilead. Here is the list of Top 10 competitors of Roivant Sciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Alcor Fund, Berkshire Hathaway & 8 others	81/100
2nd	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	81/100
3rd	Gilead 1987, Foster City (United States), Acquired	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	Jindal ventures, Menlo Ventures & 17 others	80/100
4th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	79/100
5th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Western Technology Investment, Alcor Fund ... & 16 others	76/100
6th	AstraZeneca 1999, Cambridge (United Kingdom), Public	Developer of pharmaceutical medicines for oncology and various chronic diseases	-	Digital Pharma Lab, Columbia Capital & 13 others	73/100
7th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	RTW Investments, QVT Family Office & 8 others	72/100
8th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	Gershon Capital, Kaccelerator & 7 others	71/100
9th	Novartis 1996, Basel (Switzerland), Acquired	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, Atlas Venture & 9 others	71/100
10th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, Triodos Investment Management ... & 11 others	70/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Roivant Sciences's competitors? Click here to see the top ones

Roivant Sciences has made 11 investments in companies including Proxima and Psithera. Roivant Sciences has also acquired 1 companies including Silicon Therapeutics.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jan 12, 2026	Investments	Proxima	2019	New York City (United States)
Dec 10, 2025	Investments	Psithera	2022	Watertown (United States)
Dec 07, 2022	Investments	Lokavant	2019	New York City (United States)